Dr. Kim Ekroos is one of the pioneers in the field of lipidomics, with more than 20 years of experience in the academic, industry and regulatory disciplines of lipidomics and lipid biology. His work has among others resulted in the first-ever establishment of lipidomics based lipid biomarkers in clinical diagnostics. He received his Ph.D. in biology from the Technical University in Dresden, Germany, in 2003. He did his postdoctoral work at AstraZeneca in Mölndal, Sweden. In 2016 he founded Lipidomics Consulting Ltd., a consulting business providing unique services for customers globally by designing conclusive mass spectrometry and experimental approaches to make inroads into cell, disease, biomarker and drug research and development. He is the current president of the International Lipidomics Society (ILS; www.lipidomicssociety.org) and spearheading the Lipidomics Standardization Initiative.